Schafer Klaus 4

What Happened

Klaus Schafer, a director of Altimmune, received a grant of 48,800 derivative securities (stock options) on May 1, 2026. The grant was reported at $0.00 (no cash paid at grant); this filing records the award of options rather than a cash purchase or sale. These options were awarded under the company’s non-employee director compensation policy.

Key Details

• Transaction date: 2026-05-01; Report filed: 2026-05-01.
• Grant: 48,800 options reported as derivative securities; reported price $0.00 (standard for awards).
• Vesting: Options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to continued service. (Footnotes F1–F2)
• Shares owned after transaction: Not specified in the provided Form 4.
• Filing timeliness: Filed on the same date as the reported transaction (no late filing indicated).
• Source: Award pursuant to the company’s non-employee director compensation policy (routine board compensation).

Context

This was an equity award (options) to a non-employee director — a common form of director compensation and not an immediate market purchase or sale. Options vest over time and must typically be exercised later to obtain common shares; there is no immediate cash proceeds or share sale reported with this grant. Such grants are routine and disclose potential future dilution but do not, by themselves, indicate insider buying or selling of stock.